Experimental Alzheimer's drug shows promise – but there are many hurdles still to overcome

By Ritchie Williamson, Director of research, Associate Professor in Therapeutics, University of Bradford
Stuart Dickens, Post Doctoral Research Assistant, University of Bradford

The first drug that can slow the rate of decline in Alzheimer’s patients has been found. The experimental drug, called lecanemab, is an antibody that targets the toxic clumps of amyloid protein associated with the mind-robbing disease. While these results are cause for celebration, there are still significant questions about its safety and rollout.

The full results of the phase 3 lecanemab drug trial (the final stage of testing in humans) have been published in the New England Journal of Medicine. The…

Read complete article

~	Paris 2024 Olympics: How the Games are being used to marginalize the most vulnerable

~	Why you should expect to pay more tourist taxes – even though the evidence for them is unclear

~	India election: how Narendra Modi’s BJP uses and abuses religious minorities for political purposes

~	AI may be to blame for our failure to make contact with alien civilisations

~	Lebanon: far-right group ‘Soldiers of God’ is exploiting the country’s unsettled past to stir sectarian tensions

~	The reconstruction of a 75,000-year-old Neanderthal woman’s face makes her look quite friendly – there’s a problem with that

~	OpenAI’s content deal with the FT is an attempt to avoid more legal challenges – and an AI ‘data apocalypse’

~	Silent disco: why dancing in sync brings us closer together

~	New faith schools in England could soon allocate all their places on religious grounds – here’s why that’s a bad idea

~	A ‘sponge city’ may be your home in 2050